Pharmaceutical intermediates
Lenvatinib Mesilate Intermediates
4 pharmaceutical intermediates for Lenvatinib Mesilate. Indication: Renal cell carcinoma; Endometrial carcinoma; Hepatocellular carcinoma; Thyroid cancer.
About Lenvatinib Mesilate
- Originator
- Eisai Inc
- Indication
- Renal cell carcinoma; Endometrial carcinoma; Hepatocellular carcinoma; Thyroid cancer
- Approved Date
- 02/13/2015
- DS/DP
- 10/24/2025
Available intermediates
4 intermediates currently listed for Lenvatinib Mesilate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Chloro-7-methoxyquinoline -6-carboxylic acid methyl ester | 205448-66-4 | / | / |
| 4-Chloro-7-methoxyquinoline -6-carboxamide | 417721-36-9 | / | / |
| N-(2-Chloro-4-hydroxyphenyl)-N'-cyclopropyl-urea | 796848-79-8 | / | / |
| 4-Amino-3-chlorophenol | 17609-80-2 | / | / |
Building toward Lenvatinib Mesilate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →